Reduction in constipation and laxative requirements following opioid rotation to methadone: A report of four cases

Journal of Pain and Symptom Management

Volumn 18, Issue 4, 1999, Pages 303-309

  Daeninck, Paul J ^a   Bruera, Eduardo ^a  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

Cancer pain; Constipation; Laxatives; Methadone; Opioid rotation

Indexed keywords

LAXATIVE; METHADONE; MORPHINE; OPIATE;

ADULT; AGED; ARTICLE; CANCER PAIN; CASE REPORT; CLINICAL FEATURE; CONSTIPATION; DEFECATION; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; FEMALE; HUMAN; MALE; SYMPTOM; TREATMENT OUTCOME;

ANALGESICS, OPIOID; CATHARTICS; CONSTIPATION; FEMALE; HUMANS; METHADONE; MIDDLE AGED; MORPHINE;

EID: 0032854716     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(99)00086-X     Document Type: Article

References (40)

1. Curtis E.B., Krech R., Walsh T.D. Common symptoms in patients with advanced cancer. J Palliat Care. 7:1991;25-29.
2. Sykes N.P. Constipation and diarrhea. Doyle D., Hanks G., MacDonald N. Oxford textbook of palliative medicine. 1998;513-526 Oxford University Press, Oxford.
3. Twycross R.G., Lack S.A. Symptom control in far advanced cancer. pain relief:1983;Pitman, London.
4. Derby S., Portenoy R.K. Assessment and management of opioid-induced constipation. Portenoy R.K., Bruera E. Topics in palliative care, Vol. 1. 1997;95-112 Oxford University Press, Oxford.
5. Mancini I., Bruera E. Constipation in advanced cancer patients. a review Support Care Cancer. 6:1998;356-364.
6. Ripamonti C., Zecca E., Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 70:1997;109-115.
7. De Conno F., Groff L., Brunelli C., Zecca E., Ventafridda V., Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol. 14:1996;2836-2842.
8. Vigano A., Fan D., Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain. 67:1996;115-119.
9. Bruera E., Watanabe S., Fainsinger R.L., Spachynski K., Suarez-Almazor M., Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain. 62:1995;141-146.
10. Daeninck PJ, Bruera E. Opioid use in cancer pain: Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand (in press).
11. Gorman A.L., Elliott K.J., Inturrisi C.E. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 223:1997;5-8.
12. Ebert B., Andersen S., Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 223:1997;5-8.
13. Mancini I., Hanson J., Bruera E. Opioid type and other clinical predictors of laxative dose in advanced cancer patients. a retrospective study [abstract] J Pain Symptom Manage. 15:1998;S16.
14. Folstein M.F., Folstein S., McHugh P. "Mini-mental state" a practical method for grading the cognitive state of patients for the clinician J Psych Res. 12:1975;189-198.
15. Starreveld J.S., Pols M.A., Van Wijk H.J., Bogaard J.W., Poen H., Smont A.J.P.M. The plain abdominal radiograph in the assessment of constipation. 2. Gastroenterology. 28:1990;335-338.
16. Smith R.G., Lewis S. The relationship between digital examination and abdominal radiographs in elderly patients. Age Ageing. 9:1990;142-143.
17. Ewing J. Detecting alcoholism. the CAGE questionnaire J Am Med Assoc. 252:1984;1905-1907.
18. Bruera E., Suarez-Almazor M., Velasco A., Bertolino M., Macdonald S.M., Hanson J. The assessment of constipation in terminal cancer patients admitted to a palliative care unit. a retrospective review J Pain Symptom Manage. 9:1994;515-519.
19. Bruera E., Macmillan K., Hanson J., MacDonald R.N. The Edmonton staging system for cancer pain. preliminary report Pain. 37:1989;203-209.
20. Bruera E., Watanabe S. New developments in the assessment of pain in cancer patients. Support Care Cancer. 2:1994;312-318.
21. Bruera E., Schoeller T., Wenk R., MacEachern T., Marcelino S., Suarez-Almazor M., Hanson J. A prospective multi-center assessment of the Edmonton Staging System for cancer pain. J Pain Symptom Manage. 10:1995;348-355.
22. Fainsinger R., Schoeller T., Bruera E. Methadone in the management of cancer pain. a review Pain. 52:1993;137-147.
23. Bruera E., Pereira J., Watanabe S., Belzile M., Kuehn N., Hanson J. Opioid rotation in patients with cancer pain. a retrospective comparison of dose ratios between methadone, hydromorphone and morphine Cancer. 78:1996;852-857.
24. Bruera E., Ripamonti C. Adjuvants to opioid analgesics. Patt R. Cancer pain. 1993;143-159 J. B. Lippincott, Philadelphia.
25. Martin L.A., Hagen N.A. Neuropathic pain in cancer patients. mechanisms, syndromes and clinical controversies J Pain Symptom Manage. 14:1997;99-117.
26. Watanabe S., Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage. 9:1994;442-445.
27. Ahmedzai S., Allan E., Fallon M.et al. The TTS-fentanyl multicentre study group. transdermal fentanyl in cancer pain J Drug Dev. 6:1994;93-97.
28. Ahmedzai S., Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain. preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group J Pain Symptom Manage. 13:1997;254-261.
29. Donner B., Zenz M., Tryba M., Strumpf M. Direct conversion from oral morphine to transdermal fentanyl. a multicentre study in patients with cancer pain Pain. 64:1996;527-534.
30. Donner B., Zenz M., Strumpf M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage. 15:1998;168-175.
31. Megens A.A.H.P., Artois K., Vermeire J., Meert T., Awouters F.H.L. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage. 15:1998;253-258.
32. Zenz M., Donner B., Strumpf M. Withdrawal symptoms during therapy with transdermal fentanyl (fentanyl TTS)? J Pain Symptom Manage. 9:1994;54-55.
33. Higgs C.M.B., Vella-Brincat J. Withdrawal with transdermal fentanyl [letter]. J Pain Symptom Manage. 10:1995;4-5.
34. Brooks DJ, Travers M, Wooding S, Ahmedzai S. Incidence of morphine withdrawal syndrome on changing between two mu agonists. In: Pain mechanisms and management. A scientific meeting in honor of Sampson Lipton, September 21-23 1995, Liverpool. Liverpool: Pain Research Institute, 1995:73.
35. Hunt R. Transdermal fentanyl and the opioid withdrawal syndrome [letter]. Palliat Med. 10:1996;347-348.
36. Davies A.N. Transdermal fentanyl and the opioid withdrawal syndrome [letter]. Palliat Med. 10:1996;348.
37. Dole V.P., Kreek M.J. Methadone plasma level. sustained by a reservoir of drug in the tissue Proc Natl Acad USA. 70:1973;10.
38. Mercadante S., Sapio M., Serretta R. Treatment of pain in chronic bowel subobstruction with self-administration of methadone. Support Care Cancer. 5:1997;327-329.
39. Manfredi P.L., Borsook D., Chandler S.W., Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone. clinical observations Pain. 70:1997;99-101.
40. Fitzgibbon D.R., Ready L.B. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain. 73:1997;259-261.